Abstract: To investigate the efficacy and safety of bicalutamide (Casodex) with its clinically recommended dose, the randomized early phase II study was […]

Abstract: A phase I study (open trial) of bicalutamide (Casodex), a non-steroidal antiandrogen, was conducted on 16 patients with prostatic cancer (stage […]

Abstract: Selective inhibition of type 2 5alpha-reductase has been shown to be efficacious in the treatment of benign prostatic hyperplasia. […]

Abstract: OBJECTIVES. To evaluate bicalutamide as a therapy in nearly 3000 patients with advanced prostate cancer and to determine the dose-ranging, pharmacodynamic, […]

Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials […]

Abstract: OBJECTIVES. Bicalutamide is a nonsteroidal competitive inhibitor of androgens at the androgen receptor. The level of blockade that can be […]

Abstract: OBJECTIVES: Dutasteride, a dual inhibitor of Type 1 and Type 2 5alpha-reductase, has been shown to improve disease measures in […]

Abstract: OBJECTIVES. Bicalutamide is a new, potent antiandrogen with potential efficacy in the treatment of men with advanced prostate cancer. Although […]

Abstract: Dihydrotestosterone is the main molecule responsible for androgenic alopecia. Finasteride, which reduces transformation of testosterone into dihydrotestosterone and decreases […]

Abstract: BACKGROUND: Male pattern hair loss (MPHL) is a potentially reversible condition in which dihydrotestosterone is an important etiologic factor. OBJECTIVE: Our […]